Cardiovascular & Hematological Disorders-Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth, reviews, original research articles, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
"The journal presents the latest developments in various areas of medicinal chemistry. I strongly recommend it to scientists working in the field."
Garry X. Shen
Univ. of Manitoba, Canada
Bentham Science is a science, technology, and medical (STM) publisher, providing academic researchers and industrial professionals with the latest information in diverse fields of science and technology. Our peer-reviewed scholarly journals and books have an ever-increasing readership of millions of researchers worldwide.
Bentham Science currently publishes more than 100 journals in both electronic and printed formats. Our journals cover various disciplines in pharmaceutical research and development, medical subspecialties, engineering, technology, and social sciences. The journals are indexed in recognized indexing agencies, such as Journal Citation Reports/Science Edition, MEDLINE/Index Medicus, PubMed, Scopus, Chemical Abstracts, EMBASE. ... Read More